Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips

Alexander Villalobos; Johannes L. du Pisanie; Ripal T. Gandhi; Nima Kokabi

doi:10.1055/s-0044-1779715

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2024; 41(01): 063-078
DOI: 10.1055/s-0044-1779715

How I Do It

Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips

Autor*innen

Alexander Villalobos

¹Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Johannes L. du Pisanie

¹Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Ripal T. Gandhi

¹Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Nima Kokabi

¹Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Abstract

Volltext

Referenzen

References
1 Reincke M, Schultheiss M, Doppler M. et al. Hepatic decompensation after transarterial radioembolization: a retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun 2022; 6 (11) 3223-3233
2 Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial radioembolization dosimetry in 2022. Cardiovasc Intervent Radiol 2022; 45 (11) 1608-1621
3 Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 2006; 23 (01) 64-72
4 Snyder W, Ford M, Warner G, Watson S. MIRD Pamphlet #5: Revised: Estimates of Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. New York: Society of Nuclear Medicine; 1978
5 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
6 Oken MM, Creech RH, Tormey DC. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
7 Toskich BB, Liu DM. Y90 radioembolization dosimetry: concepts for the interventional radiologist. Tech Vasc Interv Radiol 2019; 22 (02) 100-111
8 Hilgard P, Hamami M, Fouly AE. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52 (05) 1741-1749
9 Miller FH, Lopes Vendrami C, Gabr A. et al. Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial review. Radiographics 2021; 41 (06) 1802-1818
10 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
11 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021; 74 (05) 2342-2352
12 Frantz S, Matsuoka L, Vaheesan K. et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization: analysis of the RESiN Registry. J Vasc Interv Radiol 2021; 32 (06) 845-852
13 SIR-Spheres Package Insert. SIRTeX Medical Limited. Accessed March 29, 2020 at: https://www.sirtex.com/media/155126/ssl-us-13.pdf
14 Boston Scientific. Therasphere Package Insert. Accessed December 5, 2019 at: https://btgplc.com/BTG/media/TheraSphere-Documents/PDF/TheraSphere-Package-Insert_USA_Rev-14.pdf
15 Salem R, Padia SA, Lam M. et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019; 46 (08) 1695-1704
16 Elsayed M, Cheng B, Xing M. et al. Comparison of Tc-99m MAA planar versus SPECT/CT imaging for lung shunt fraction evaluation prior to Y-90 radioembolization: Are we overestimating lung shunt fraction?. Cardiovasc Intervent Radiol 2021; 44 (02) 254-260
17 Gabr A, Ranganathan S, Mouli SK. et al. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol 2020; 72 (06) 1151-1158
18 Kessler J, Park JJ. Yttrium-90 radioembolization after local hepatic therapy: How Prior treatments impact patient selection, dosing, and toxicity. Tech Vasc Interv Radiol 2019; 22 (02) 112-116
19 Zimmermann M, Schulze-Hagen M, Liebl M. et al. Safety and efficacy of Y-90 radioembolization after prior major hepatic resection. Cardiovasc Intervent Radiol 2017; 40 (08) 1206-1212
20 Lam MGEH, Abdelmaksoud MHK, Chang DT. et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 87 (02) 323-329
21 Lam MGEH, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2013; 36 (05) 1320-1328
22 Badar W, Van Ha T, Zangan S. et al. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol 2021; 94 (1119) 20200752
23 Srinivas S, Rose SC, Al Jammal O. et al. Boosted-dose yttrium-90 radiation segmentectomy or lobectomy for hepatocellular carcinoma refractory to prior transarterial embolization or chemoembolization: a single institution retrospective case series. Cardiovasc Intervent Radiol 2023; 46 (04) 460-469
24 Feng MY, Chan LL, Chan SL. Drug treatment for advanced hepatocellular carcinoma: first-line and beyond. Curr Oncol 2022; 29 (08) 5489-5507
25 Torkian P, Haghshomar M, Farsad K, Wallace S, Golzarian J, Young SJ. Cancer immunology: impact of radioembolization of hepatocellular carcinoma on immune response modulation. AJR Am J Roentgenol 2023; 220 (06) 863-872
26 Yu Q, Wang Y, Ungchusri E. et al. Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: a preliminary report of safety and effectiveness. J Clin Oncol 2023; 41 (16 Suppl): e16231-e16231
27 Kennedy A, Brown DB, Feilchenfeldt J. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017; 8 (06) 1079-1099
28 Westcott MA, Coldwell DM, Liu DM, Zikria JF. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol 2016; 1 (04) 351-364
29 TheraSphere Now - Boston Scientific. Accessed October 6, 2023 at: https://www.bostonscientific.com/en-US/products/cancer-therapies/therasphere-y90-glass-microspheres/ordering-information/therasphere-now.html
30 Sirtex - FLEXdose Delivery Programme. Accessed October 6, 2023 at: https://www.sirtex.com/eu/professionals/specialties/interventional-radiology/flexdose-delivery-programme/
31 Salem R, Padia SA, Lam M. et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2023; 50 (02) 328-343
32 Levillain H, Bagni O, Deroose CM. et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48 (05) 1570-1584
33 Kokabi N, Arndt-Webster L, Chen B. et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging 2023; 50 (06) 1743-1752
34 Villalobos A, Arndt L, Cheng B. et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres. J Vasc Interv Radiol 2023; 34 (07) 1226-1234
35 Jernigan SR, Osborne JA, Mirek CJ, Buckner G. Selective internal radiation therapy: quantifying distal penetration and distribution of resin and glass microspheres in a surrogate arterial model. J Vasc Interv Radiol 2015; 26 (06) 897-904.e2
36 Snoeijink TJ, Vlogman TG, Roosen J, Groot Jebbink E, Jain K, Nijsen JFW. Transarterial radioembolization: a systematic review on gaining control over the parameters that influence microsphere distribution. Drug Deliv 2023; 30 (01) 2226366
37 Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med 2014; 55 (01) 135-140
38 Chiesa C, Sjogreen-Gleisner K, Walrand S. et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Phys 2021; 8 (01) 1-44
39 Kurilova I, Beets-Tan RGH, Ulaner GA. et al. ⁹⁰Y resin microspheres radioembolization for colon cancer liver metastases using full-strength contrast material. Cardiovasc Intervent Radiol 2018; 41 (09) 1419-1427
40 Maxwell AWP, Mendoza HG, Sellitti MJ. et al. Optimizing ⁹⁰Y particle density improves outcomes after radioembolization. Cardiovasc Intervent Radiol 2022; 45 (07) 958-969
41 Struycken L, Patel M, Kuo P, Hennemeyer C, Woodhead G, McGregor H. Clinical and dosimetric implications of calculating lung shunt fraction for hepatic ⁹⁰Y radioembolization using SPECT/CT versus planar scintigraphy. AJR Am J Roentgenol 2022; 218 (04) 728-737
42 Alsultan AA, Smits MLJ, Barentsz MW, Braat AJAT, Lam MGEH. The value of yttrium-90 PET/CT after hepatic radioembolization: a pictorial essay. Clin Transl Imaging 2019; 7 (04) 303-312
43 Louie JD, Kothary N, Kuo WT. et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol 2009; 20 (05) 606-613
44 O'Connor PJ, Pasik SD, van der Bom IM, Bishay V, Radaelli A, Kim E. Feasibility of yttrium-90 radioembolization dose calculation utilizing intra-procedural open trajectory cone beam CT. Cardiovasc Intervent Radiol 2020; 43 (02) 295-301
45 Yang ZF, Poon RTP. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken) 2008; 291 (06) 721-734
46 Villalobos A, Soliman MM, Majdalany BS. et al. Yttrium-90 radioembolization dosimetry: what trainees need to know. Semin Intervent Radiol 2020; 37 (05) 543-554
47 Bastiaannet R, Kappadath SC, Kunnen B, Braat AJAT, Lam MGEH, de Jong HWAM. The physics of radioembolization. EJNMMI Phys 2018; 5 (01) 22
48 Gabr A, Kulik L, Mouli S. et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology 2021; 73 (03) 998-1010
49 Johnson GE, Padia SA. Yttrium-90 radiation segmentectomy. Semin Intervent Radiol 2020; 37 (05) 537-542
50 Gabr A, Riaz A, Johnson GE. et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 2021; 48 (02) 580-583
51 Gates VL, Hickey R, Marshall K. et al. Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. Eur J Nucl Med Mol Imaging 2015; 42 (13) 2038-2044
52 Ahmed A, Stauffer JA, LeGout JD. et al. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure. J Gastrointest Oncol 2021; 12 (02) 751-761
53 Entezari P, Gabr A, Kennedy K, Salem R, Lewandowski RJ. Radiation lobectomy: an overview of concept and applications, technical considerations, outcomes. Semin Intervent Radiol 2021; 38 (04) 419-424
54 Palard X, Edeline J, Rolland Y. et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2018; 45 (03) 392-401
55 Ali A, Ahmed M, Weinstein J. et al. Abstract No. 559 Radiation lobectomy with resin microspheres using medical internal radiation dosimetry model. J Vasc Interv Radiol 2020; 31 (03) S244
56 Villalobos A, Gandhi RT, Kokabi NA. Practical, Case-Based Approach to Yttrium-90 Radioembolization Dosimetry in the Liver. Endovascular Today. Published October 2021 . Accessed October 23, 2023 at: https://evtoday.com/articles/2021-oct/a-practical-case-based-approach-to-yttrium-90-radioembolization-dosimetry-in-the-liver
57 Matsumoto MM, Mouli S, Saxena P. et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis. Cardiovasc Intervent Radiol 2021; 44 (07) 1070-1080
58 Braat AJAT, Smits MLJ, Braat MNGJA. et al. 90Y hepatic radioembolization: an update on current practice and recent developments. J Nucl Med 2015; 56 (07) 1079-1087
59 Garin E, Tselikas L, Guiu B. et al; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29
60 Webster LA, Villalobos A, Cheng B. et al. Correlation of non-tumoral liver dose with treatment-related adverse events in patients with hepatocellular carcinoma treated with glass-based yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2023; 46 (01) 60-68
61 Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB (Oxford) 2022; 24 (02) 152-160
62 Teyateeti A, Mahvash A, Long JP. et al. Survival outcomes for yttrium-90 transarterial radioembolization with and without sorafenib for unresectable hepatocellular carcinoma patients. J Hepatocell Carcinoma 2020; 7: 117-131
63 Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for ⁹⁰ Y radioembolization with glass microspheres: evaluating the fidelity of ^99m Tc-MAA and partition model predictions. Med Phys 2020; 47 (10) 5333-5342
64 Salem R, Thurston KG. Radioembolization with ⁹⁰yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
65 Chiesa C, Mira M, Bhoori S. et al. Radioembolization of hepatocarcinoma with ⁹⁰Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging 2020; 47 (13) 3018-3032